Literature DB >> 21085895

Evaluation of the immune humoral response of Brazilian patients with Rubinstein-Taybi syndrome.

L C Torres1, S M M Sugayama, C Arslanian, M M Sales, M Carneiro-Sampaio.   

Abstract

Rubinstein-Taybi syndrome (RTS) is a rare developmental disorder characterized by craniofacial dysmorphisms, broad thumbs and toes, mental and growth deficiency, and recurrent respiratory infections. RTS has been associated with CREBBP gene mutations, but EP300 gene mutations have recently been reported in 6 individuals. In the present study, the humoral immune response in 16 RTS patients with recurrent respiratory infections of possible bacterial etiology was evaluated. No significant differences between patients and 16 healthy controls were detected to explain the high susceptibility to respiratory infections: normal or elevated serum immunoglobulin levels, normal salivary IgA levels, and a good antibody response to both polysaccharide and protein antigens were observed. However, most patients presented high serum IgM levels, a high number of total B cell and B subsets, and also high percentiles of apoptosis, suggesting that they could present B dysregulation. The CREBBP/p300 family gene is extremely important for B-cell regulation, and RTS may represent an interesting human model for studying the molecular mechanisms involved in B-cell development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21085895     DOI: 10.1590/s0100-879x2010007500119

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  2 in total

1.  Further peer review failures.

Authors:  Horacio Rivera
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 2.  Rubinstein-Taybi syndrome: clinical features, genetic basis, diagnosis, and management.

Authors:  Donatella Milani; Francesca Maria Paola Manzoni; Lidia Pezzani; Paola Ajmone; Cristina Gervasini; Francesca Menni; Susanna Esposito
Journal:  Ital J Pediatr       Date:  2015-01-20       Impact factor: 2.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.